The first transcript of the 2021 stem cell epidemic came out!

In the past 2020, stem cells have achieved phased results in the treatment of neo-crown pneumonia.
the beginning of 2021, the good news of stem cells treating new coronary pneumonia has come to us.
January 5th, a new study in the journal Stem Cell Translational Medicine showed that inter-umbilical cord-filled stem cells can significantly improve survival and recovery time in patients with acute respiratory distress syndrome in neo-coronary pneumonia.
this was based on a randomized double-blind controlled trial of 24 subjects.
the trial, 24 subjects were randomly divided into the trial and control groups, with 12 patients in each group.
group received two intravenous infusions of interstumined stem cells, each infusion of 100 million cells, at intervals of 72 hours.
control group also received two infusions, but did not contain interstate stem cells.
two groups of patients received the best care.
Figure: Significant improvement in recovery time in patients in the interstume stem cell therapy group: Improvement in survival in patients in the mesochargic stem cell therapy group showed that interstate stem cell therapy was safe and significantly reduced inflammatory cytokines in patients, significantly improving survival and recovery time.
found that there were fewer serious adverse events in the interstumogenic stem cell treatment group than in the control group.
this is why researchers believe that inter-umbilical cord-filled stem cell infusion therapy is safe and beneficial for patients with acute respiratory distress syndrome in neo-coronary pneumonia.
the outbreak of neo-coronary pneumonia, it has been known that the mortality rate from neo-coronavirus infection is associated with acute respiratory distress syndrome and multi-organ failure caused by the outbreak of neo-coronary stem cells.
Although treatments such as dexamisson and recovery plasma have been found, there is still a need to develop therapies that regulate inflammatory responses, shorten disease progressions and further improve survival rates.
-charged stem cells can not only suppress excessively strong immune storms, but also enhance the body's immunity when immunity is low, and promote endogenetic repair and regeneration mechanisms in the lungs after new coronavirus infections.
interstitial stem cells can also regulate the immune system by inhibiting inflammatory cytokines produced by lymphocytes and induce the production of anti-inflammatory cytokines.
, interstate stem cell therapy promises to provide a unique treatment option for patients with the new coronavirus.
countries around the world have adopted interstity stem cells to treat patients with severe neo-coronary pneumonia.
based on information from the U.S. Clinical Trials Database, searched using the keywords "COVID-19" and "mesenchymal stem cell", a total of 68 interstumined stem cells were registered for the whole of 2020.
Special Committee on Regenerative Medicine in Kyushua, Japan, approved a programme for the use of self-filled stem cells to treat the after-effects of neo-coronary pneumonia.
March 2020, the U.S. Biomedical Advanced Research and Development Agency (BARDA) evaluated MultiStem® a interstumogenic stem cell treatment product, as a highly relevant therapy for COVID-19.
has the potential to significantly improve the lives of patients and has the potential to be a resource for the treatment of COVID-19 and other respiratory diseases.
In China, after the outbreak of neo-coronary pneumonia in early 2020, research projects on inter-regional interstitity stem cells to treat severe neo-coronavirus pneumonia have been approved one after another, and have become emergency research projects for new coronavirus prevention and control or emergency special projects for national science and technology.
, such as zhengzhou University affiliated henan Provincial People's Hospital, "interstitational stem cells (MSC) treatment of coronavirus caused by severe pneumonia clinical research" has become a new type of coronavirus prevention and control emergency research projects in Henan Province.
clinical study led by academician Wang Fusheng to treat neo-crown pneumonia has been listed as an urgent special project of national science and technology.
, interstumable stem cells have become a highly valued anti-epidemic strategy.
perinatal tissue: to provide the "campaign" with interstume stem cell source umbilical cord and placenta and other perinatal tissue rich in interstate stem cells, has become an important regenerative medicine resources to fight the new coronary pneumonia.
according to data from the China Clinical Trials Registry, there have been several treatment studies of new coronary pneumonia in China using interstate stem cells from perinatal tissue sources.
study, published in 2021, the team used interstitiotic stem cells from umbilical cord sources and believed they were beneficial in treating acute distress syndrome associated with new coronary pneumonia.
In fact, in August 2020, a team of chinese academicians published their findings in the journal Nature, confirming the safety and clinical benefits of umbilical cord-filled stem cells for patients with common and severe neocyctic pneumonia.
2020, a study published in the journal Stem Cell Translational Medicine found that the best source of interstate stem cells for treating organ failure associated with neoclerosis is the placenta, or cells from erypotent stem cells.
it has been known that angiosin-converting enzyme 2 (ACE2) is a new coronavirus that enters cells.
researchers analyzed the expression of ACE2 in interstate-charged stem cells from different sources.
found that ACE2 was highly expressed in adult bone marrow, adipose tissue, or inter-umbilical cord-filled stem cells.
And in the early transmission of low expression in interstate stem cells from placental sources, and only in the early transmission of culture, intercharged stem cells from human embryonic stem cells or human-induced erythmatic stem cells also express very low levels of ACE2, which reduces the chance that the virus will pass into the target cell.
With the development of the epidemic, there are more and more registered projects worldwide to treat neo-coronary pneumonia using perinatal tissue-filled stem cells, and projects for other diseases have been registered, which means that perinatal inter-tissue perinatal interstitiochargic stem cells have been more widely recognized.
the invasion of the new coronavirus, interstate stem cells have brought new hope to human medicine.
are widely found in human body, with the development of science, people realize that perinatal tissue is a natural treasure trove of interstumogenic stem cells, which provides protection for human health.
At present, half of the interstate stem cell therapy obtained clinical approval in China uses interstume stem cells from perinatal tissue sources, and more and more disease types are involved, I believe that the future perinatal tissue sources of interstume stem cells will bring more possibilities for the treatment of diseases.
references: sic) Umbilical cord mesenchymal stem cells for COVID-19 acute acute distressy distress syndrome: A double-blind, phase 1/2a, randomized controled trial center investigation of the relevant sources of the mesenchy stemmal cells for cell therapy COVID-19-associated organ failure. Stem Cells Transl Med. Ge XY, Li JL, Yang XL, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013; 503:535-538.